Summary
Cancer cells are characterized by epigenetic dysregulation, including global genome hypomethylation, regional hypo- and hypermethylation, histone modifications, and disturbed genomic imprinting. These alterations can be used as markers in cancer epidemiology to assess risk as well as follow-up of the disease. Some of the methylation markers can be assayed on microarray chips on which a very small amount of sample is needed, and the assays are robust and the markers have high specificity and sensitivity. Implication of epigenetic markers in cancer detection, diagnosis, prognosis, control, and cancer epidemiology is discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jones, P. A., and Baylin, S. B. (2007) The epigenomics of cancer. Cell 128, 683–692.
Jones, P. A., and Martienssen, R. (2005) A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. Cancer Res 65, 11241–11246.
Marjoram, P., Chang, J., Laird, P. W., and Siegmund, K. D. (2006) Cluster analysis for DNA methylation profiles having a detection threshold. BMC bioinformatics 7, 361.
Siegmund, K. D., Levine, A. J., Chang, J., and Laird, P. W. (2006) Modeling exposures for DNA methylation profiles. Cancer Epidemiol Biomarkers Prev 15, 567–572.
Verma, M., Seminara, D., Arena, F. J., John, C., Iwamoto, K., and Hartmuller, V. (2006) Genetic and epigenetic biomarkers in cancer: improving diagnosis, risk assessment, and disease stratification. Mol Diagn Ther 10, 1–15.
Eads, C. A., Danenberg, K. D., Kawakami, K., Saltz, L. B., Blake, C., Shibata, D., Danenberg, P. V., and Laird, P. W. (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28, E32.
Fiegl, H., Millinger, S., Goebel, G., Muller-Holzner, E., Marth, C., Laird, P. W., and Widschwendter, M. (2006) Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 66, 29–33.
Eads, C. A., Lord, R. V., Wickramasinghe, K., Long, T. I., Kurumboor, S. K., Bernstein, L., Peters, J. H., DeMeester, S. R., DeMeester, T. R., Skinner, K. A., and Laird, P. W. (2001) Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61, 3410–3418.
Genereux, D. P., Miner, B. E., Bergstrom, C. T., and Laird, C. D. (2005) A population-epigenetic model to infer site-specific methylation rates from double-stranded DNA methylation patterns. Proc Natl Acad Sci U S A 102, 5802–5807.
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., and Laird, P. W. (2007) Epigenetic stem cell signature in cancer. Nat Genet 39, 157–158.
Burden, A. F., Manley, N. C., Clark, A. D., Gartler, S. M., Laird, C. D., and Hansen, R. S. (2005) Hemimethylation and non-CpG methylation levels in a promoter region of human LINE-1 (L1) repeated elements. J Biol Chem 280, 14413–14419.
Stoger, R., Kajimura, T. M., Brown, W. T., and Laird, C. D. (1997) Epigenetic variation illustrated by DNA methylation patterns of the fragile-X gene FMR1. Hum Mol Genet 6, 1791–1801.
Anton, M., Horky, M., Kuchtickova, S., Vojtesek, B., and Blaha, O. (2004) Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears. Ceska Gynekol 69, 3–6.
Allison, S. J., and Milner, J. (2003) Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidy. Cancer Res 63, 6674–6679.
Gandhi, M., Medvedovic, M., Stringer, J. R., and Nikiforov, Y. E. (2006) Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 25, 2360–2366.
Chen, K. G., Wang, Y. C., Schaner, M. E., Francisco, B., Duran, G. E., Juric, D., Huff, L. M., Padilla-Nash, H., Ried, T., Fojo, T., and Sikic, B. I. (2005) Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res 65, 9388–9397.
Puccetti, E., Obradovic, D., Beissert, T., Bianchini, A., Washburn, B., Chiaradonna, F., Boehrer, S., Hoelzer, D., Ottmann, O. G., Pelicci, P. G., Nervi, C., and Ruthardt, M. (2002) AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res 62, 7050–7058.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kumar, D., Verma, M. (2009). Methods in Cancer Epigenetics and Epidemiology. In: Verma, M. (eds) Cancer Epidemiology. Methods in Molecular Biology, vol 471. Humana Press. https://doi.org/10.1007/978-1-59745-416-2_14
Download citation
DOI: https://doi.org/10.1007/978-1-59745-416-2_14
Publisher Name: Humana Press
Print ISBN: 978-1-58829-987-1
Online ISBN: 978-1-59745-416-2
eBook Packages: Springer Protocols